Option chain shows key data for PharmaTher Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PharmaTher Holdings.

PharmaTher Holdings (OTC:PHRRF) Stock, Option Chain

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.

Cannabis

News

Penny Stocks

Psychedelics

Markets

ATAI

CMND

CMPS

CYBN

IGXT

LOBEF

PHRRF

PMBHF

TSLA

Welcome to Benzinga&#39;s weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024. 

Psychedelics Headlines: MDMA &amp; Coping Skills In PTSD, LSD&#39;s Perceived Risks, Knowledge Gaps, Surveys &amp; More

Small Cap

DMTTF

DRUG

ENVB

GHRS

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

IXHL

LSDI

MNMD

PSIL

SILO

Depression Relief: Possible Therapy Boost With DMT &amp; SSRIs Small Pharma Clinical Results

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

Psyched: DMT &amp; SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics &amp; More

Guidance

Health Care

General

The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product. 

PharmaTher Is &#39;One Step Closer To Being A Ketamine Leader&#39; Due To FDA Acceptance

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Press Releases

PharmaTher Announces Update on FDA New Drug Application for Ketamine

PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

PharmaTher CEO Issues Letter to Shareholders

PharmaTher Provides Update on FDA New Drug Application for Ketamine

PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine

Comments

PharmaTher Holdings

PharmaTher Holdings (PHRRF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga